ClinicalTrials.gg
Not yet recruitingNCT07412548AR-MHDUpdated Feb 17, 2026

Autogenic Relaxation and Murottal Therapy in Hemodialysis Patients

An interventional study of Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy and listening to dangdut music in Chronic Kidney Disease Stage V, End-Stage Renal Disease and Hemodialysis, sponsored by Universitas Muhammadiyah Surakarta. Not yet recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Universitas Muhammadiyah Surakarta · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients. A pretest-posttest control group design will be used involving 76 participants undergoing routine hemodialysis. Participants will be assigned to an intervention group receiving structured autogenic relaxation followed by murottal therapy and a control group receiving standard care with music listening. Anxiety, sleep quality, and hemodynamic parameters will be measured at baseline and after a 6-week intervention period. The findings are expected to support the use of non-pharmacological and spiritual-based interventions in improving psychological and physiological outcomes in hemodialysis patients.

Read the detailed description

This study applies a quasi-experimental pretest-posttest control group design. The intervention group receives structured autogenic relaxation followed by Surah Ar-Rahman murottal therapy for 10-15 minutes per session, twice weekly for six weeks. The control group receives standard hemodialysis care with music listening. Anxiety, sleep quality, and hemodynamic parameters are assessed before and after the intervention.

02

Conditions studied

  • Chronic Kidney Disease Stage V
  • End-Stage Renal Disease
  • Hemodialysis

Keywords

  • Autogenic Relaxation
  • Murottal Therapy
  • Anxiety
  • Sleep Quality
  • Hemodynamics
03

In context

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

This study's planned enrollment of 76 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Universitas Muhammadiyah Surakarta is the lead sponsor of 11 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with stage V chronic kidney disease.
  2. Undergoing scheduled hemodialysis at least twice a week for 6 weeks.
  3. Outpatients and aged 18-65 years.
  4. Muslim.
  5. Cooperative and able to communicate verbally.
  6. Willing to be a respondent by signing an form.

Exclusion criteria

Exclusion Criteria:

  1. Having a severe heart condition or an unstable critical condition.
  2. Having a severe psychiatric disorder (schizophrenia, major depression).
  3. Having a cognitive, hearing, or speech disorder that impedes communication.
  4. Taking antidepressants, anxiolytics, or neuroleptics that may affect psychological measurement results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Autogenic Relaxation and Murottal Therapy Surah Ar-Rahman

    Participants in this group receive structured autogenic relaxation followed by Surah Ar-Rahman murottal therapy during hemodialysis sessions. The intervention is administered twice weekly for six weeks, with each session lasting 10-15 minutes. The procedure is conducted by trained nurses under researcher supervision in a quiet and comfortable environment.

    Behavioral: Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy

  • Active comparator
    Standard Care

    listening to dangdut music for 10 to 15 minutes within 6 weeks

    Other: listening to dangdut music

Interventions

  • BehavioralAutogenic Relaxation and Surah Ar-Rahman Murottal Therapy

    A structured non-pharmacological intervention consisting of autogenic relaxation techniques including breathing regulation, muscle relaxation, and self-suggestion, followed by listening to Surah Ar-Rahman murottal recitation using earphones. Each session lasts 10-15 minutes and is conducted twice weekly for six weeks during routine hemodialysis.

  • Otherlistening to dangdut music

    listening to dangdut music for 10 to 15 minutes within 6 weeks

06

What researchers measure

Primary outcomes

  1. Anxiety

    Change in anxiety level measured using the Zung Self-Rating Anxiety Scale (ZSAS; range 20-80), where higher scores indicate greater anxiety, from baseline to after completion of the 6-week intervention.

    Time frame: Baseline and after completion of the 6-week intervention

  2. Sleep Quality

    Change in sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI; range 0-21), where higher scores indicate poorer sleep quality, from baseline to after completion of the 6-week intervention.

    Time frame: Baseline and after completion of the 6-week intervention.

  3. Blood Presure

    Change in systolic blood pressure (mmHg), measured using a calibrated digital sphygmomanometer, from baseline to after completion of the 6-week intervention.

    Time frame: Baseline and after completion of the 6-week intervention

  4. Heart Rate

    Change in heart rate (beats per minute, bpm), measured using a digital bedside patient monitor, from baseline to after completion of the 6-week intervention.

    Time frame: Baseline and after completion of the 6-week intervention

07

Study locations

1 site
  • Indriati Hospital
    Sukoharjo, Central Java 57552, Indonesia
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for May 2026, 2 months later.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 2 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 17, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
May 31, 2026
CompletionEst.
Jun 30, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07412548
Lead sponsor
Universitas Muhammadiyah Surakarta
Responsible party
Dyan Kurniasari (Graduate Researcher, Universitas Muhammadiyah Surakarta) — Principal investigator
First posted
Feb 17, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
May 31, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Dyan Kurniasari, S.Kep.,Ns
Contact
j218240018@student.ums.ac.id
+628122593391

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion